Abstract | Advances in basic immunology have led to an improved understanding of the interactions between the immune system and tumours, generating renewed interest in approaches that aim to treat cancer immunologically. As clinical and preclinical studies of tumour immunotherapy illustrate several immunological principles, a review of these data is broadly instructive and is particularly timely now that several agents are beginning to show evidence of efficacy. This is especially relevant in the case of prostate cancer, as recent approval of sipuleucel-T by the US Food and Drug Administration marks the first antigen-specific immunotherapy approved for cancer treatment. Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context.
In developed countries, prostate cancer is the most common cancer in men, and it ranks third overall in terms of mortality (behind lung cancer and colon cancer) 1 . Localized disease is treated surgically or with radiation therapy 2 or, alternatively, may be monitored closely if the cancer is thought to be of sufficiently low risk 3 . If disease returns after initial surgery or radia tion therapy, this recurrent disease can be treated with androgen ablation (chemical castration or surgical castration) or observed until metastatic progression. Metastatic prostate cancer is initially treated with androgen abla tion, but most patients eventually become refractory to this treatment, developing castration-resistant disease, for which the primary treatment option is chemo therapy 4, 5 . This paucity of therapeutic options, as well as their associated morbidity, has led to a search for new treatments; immunotherapy, in which the patients' immune system is targeted to induce an antitumour response, is a rapidly evolving treatment option. In many ways, prostate cancer is a typical epithelial adeno carcinoma, so the immunotherapy approaches that are being developed for this disease provide insights that are also applicable to other epithelial can cer types. In this Review, we first briefly discuss the basic biology and natural history of prostate cancer, focusing on issues that relate to immunotherapy. We then outline some of the immunotherapy approaches that have advanced to later stage clinical trials, with an emphasis on the immunological and clinical insights provided by these studies.
Immunological characteristics of prostate cancer
With several notable exceptions, most human cancers develop in immunologically intact hosts. So, the pro gression of tumours from lowgrade, localized disease to metastasis involves an interaction between the tumour cells and the host immune system; here, we focus on what is known regarding that interaction in prostate cancer.
Role of inflammation in the development of prostate cancer. As is the case for most types of cancer, the pre cise aetiology of prostate cancer is unknown; however, a great deal of literature supports the hypothesis that both genetic 6 and environmental 7 factors are impor tant. Interestingly, human 8 and animal studies indicate that inflammation might have a role in prostate cancer development, as well as in the progression from organconfined to metastatic disease 9, 10 . Inflammation is also thought to have a role in the development of many other human cancers; welldescribed examples include gastric, colon and liver cancer 11 . A causal rela tionship between ongoing inflammation and prostate cancer has yet to be established, but substantial epi demiological evidence indicates that prostate cancer is more common in demographic groups with a greater degree of baseline inflammation 8 . Unfortunately, neither the aetiology nor the precise immunological characteristics of intraprostatic inflammation are well understood. 
Localized disease
In prostate cancer, this usually refers to disease that does not extend beyond the prostate gland itself, which can be treated with radiotherapy, surgery or the removal of androgens.
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Androgen
A type of steroid hormone that controls the male characteristics of vertebrate animals. Testosterone is the best example of an androgen important in prostate cancer, but its metabolite, dihydrotestosterone, is the more potent form in most tissues.
Chemical castration
A therapy to decrease circulating androgen levels through pharmacological intervention. In patients with prostate cancer, this is carried out using leuteinizing hormone-releasing hormone (LHRH) antagonists, which act on the hypothalamus to centrally mediate a decrease in testosterone secretion.
Surgical castration
The removal of the testicles to decrease circulating androgen levels. It should be noted that androgens are also secreted by the adrenal cortex, so that surgical castration does not completely eliminate androgens from the blood.
Castration-resistant disease
Prostate cancer that can be shown to be progressing through a rising prostatespecific antigen level or by imaging studies, despite a low or undetectable level of testosterone in the blood following chemical or surgical castration.
and regulatory T (T Reg )
12-15 cell populations. Intra prostatic CD8 + T cells in humans are nonfunctional and do not upregulate activation markers such as CD69 or CD137 in response to stimulation with phorbol 12myristate 13acetate (PMA) and ionomycin 16 . These data are consistent with those obtained using antigen specific CD8 + T cells isolated from melanoma lesions 17 , as well as with transgenic mouse models of prostate cancer (see below). In terms of immunotherapy, these results indicate that prostate cancer vaccination is targeted at an organ with a preexisting and complex pattern of inflammation that might be contributing to disease progression.
Early-stage prostate cancer. like most solid tumours, prostate cancer generally progresses through a series of stages, known as clinical states 18 (FIG. 1) . In developed countries, many cases of prostate cancer are initially detected by monitoring the levels of prostatespecific antigen (PSA) in the blood
. Increased (or chang ing) levels of PSA prompt a biopsy, and a diagnosis of prostate cancer is based on microscopic evaluation of the biopsy specimen. Diagnosis generally leads to an attempt at local treatment, with either surgery or radio therapy. For up to 80% of surgically treated men, local treatment is successful in that metastatic disease does not occur within 15 years 19 . When disease does recur, the initial manifestation is often a rising PSA level without radiologically detectable metastases, a clinical state known as biochemical progression 20, 21 . An analo gous state occurs in some gastrointestinal cancers, in which an increasing level of carcinoembryonic antigen (CeA) can be detected before progression as deter mined by radiographic imaging 22 . From an immuno logical perspective, biochemical recurrence provides a unique opportunity for immunological intervention in patients with cancer, as the many immunosuppressive mechanisms (such as T Reg cells, myeloidderived sup pressor cells (MDSCs) and transforming growth factorβ (TgFβ)) 23 associated with an advanced tumour burden are expected to be at a minimum at this stage. However, it is difficult to select appropriate endpoints for clinical trials in patients with biochemically recurrent cancers, as neither PSA nor CeA level is a validated surrogate endpoint acceptable for drug registration
. More traditional clinical endpoints, such as the development of overt metastases, might not occur for many years 19 , leading to unacceptably long followup times for trials with such endpoints.
Late-stage prostate cancer. Prostatic epithelial cells are broadly dependent on androgens for survival; hence men with biochemically recurrent disease can be treated with androgen ablation, through either surgical or chemical castration 24 . Although an overall survival benefit for androgen ablation in men with bio chemically recurrent disease is not well supported by large, randomized clinical trials, it is of interest to note that this commonly used therapy has many immuno logical effects, several of which would be expected to increase the efficacy of cancer immunotherapy 25 . Initial observations in this regard came from a study showing that androgen ablation before prostate cancer surgery resulted in a substantial CD4 + T cell infiltration into the gland, and that the infiltrating cells expressed a restricted pattern of use of the T cell receptor βchain variable region (Vβ) -such an oligoclonal response is consistent with an antigenspecific response 26 . These findings were well supported by a more recent compre hensive analysis of the postcastration immuno logical infiltrate in the prostate gland, in which an increased CD8 + T cell infiltrate was noted as well 27 . Using an autochthonous mouse prostate cancer model, we found that androgen ablation decreases CD4 + T cell toler ance to a prostate cancerassociated antigen: adoptively transferred, clonotypic CD4 + T cells could respond to specific vaccination after androgen ablation but not in intact, tumourbearing mice 28 . Perhaps even more intriguing are reports showing that androgen ablation reverses the thymic involution that normally occurs with aging, resulting in increased output of naive T cells 29 . Taken together, these data strongly support the notion that androgen ablation, through its effects on boosting the prostatespecific immune response, could have an additive effect with immunotherapy, a princi ple that has been formally evaluated in several clinical trials 30 . Interestingly, the relative timing of androgen ablation and immunotherapy could be crucial; one study showed that applying immunotherapy before castration was more effective than the converse 31 . eventually, many men with prostate cancer develop metastatic disease, despite androgen ablation. This dis ease state is known as metastatic, castrationresistant prostate cancer and is the state in which most immu notherapy approaches have been clinically evaluated. These men have a median survival of ~16 months 4, 5 , allowing the timely completion of trials with a survival endpoint. However, from an immunological perspective, 33, 34 .
Immunology of prostate cancer in mice
In addition to the human epidemiological and clinical data discussed above, immunological data from mouse models could also potentially inform clinical trial design and interpretation. In this regard, the develop ment of the TRAMP model (transgenic adenocarcinoma of the mouse prostate model) 35 has provided a unique opportunity to investigate T cell responses in develop ing prostate tumours in vivo. This work has included studies of the endogenous T cell repertoire, as well as adoptive T cell transfer experiments. Reassuringly, the results obtained have been generally consistent, with several groups reporting the development of CD8 + T cell tolerance to evolving tumours [36] [37] [38] [39] [40] [41] . These results corroborate earlier studies in other spontaneous mouse cancer models 42, 43 , providing broad support to the notion that evolving tumours are associated with CD8 + T cell tolerance. CD4 + T cell tolerance to prostate tumours has been less well addressed but also seems to be associated with tumour progression 34, 44 . We observed specific CD4 + T cell tolerance to prostate specific antigens in TRAMP mice as young as 6 weeks of age 44 -before overt tumours can be detected patho logically -supporting the notion that the development of specific T cell tolerance is an early event in cancer progression. We also found that naive CD4 + T cells adopted a regulatory phenotype after encounter with tumour antigen 44 , which is consistent with the hypo thesis that tumours can induce T Reg cell proliferation and/or development. More recent studies have extended this idea to CD8 + T cells, which might also develop a reg ulatory phenotype after contact with tumour antigen 15, 45 . overall, these human and mouse data support a model whereby evolving tumours result in the proliferation of T cells with an anticancer potential but that, in the absence of some intervention, such cells exist in a nonfunctional or anergic state.
Antigen-specific immunotherapy
The goal of most approaches to cancer immunotherapy is to activate a population of effector T cells, which can then traffic to evolving tumours and mediate the specific lysis of cancer cells. In antigenspecific approaches, a tumour associated antigen is directly targeted, either by loading that antigen onto antigenpresenting cells (APCs) ex vivo or by incorporating the antigen into a vaccine vector at a protein or DnA level. Below, we summarize the antigen specific immunotherapy approaches for prostate cancer that have progressed furthest in clinical trials. Although a large number of target antigens could have potentially been selected for prostate cancer, a great deal of clinical work in this area has focused on PSA as a target, most probably because of its longstanding clinical use as a serum marker for the disease. other prostateassociated antigens include prostatic acid phosphatase (PAP) and prostatespecific membrane antigen (PSMA; also known as gPCII), which is expressed on the vasculature in sev eral types of cancer 46 . The expression pattern of PSA is nearly ideal for its use as an immunotherapy target; it is expressed fairly exclusively by prostate cancer cells and by nontransformed prostate epithelial cells, making it a specific marker of prostate tissue. notably, a tumour specific protein is generally not thought to be necessary because, at the time of vaccine treatment, most men with prostate cancer have undergone primary therapy, and the only remaining PSAexpressing cells would be expected to be tumour cells. A few studies also indicate a role for PSA in the initiation and progression of pros tate cancer, making it a potentially functional target as well 47 . In the absence of immunotherapy, however, T cell responses to PSA are difficult to detect in patients with laterstage prostate cancer, which indicates that, similar to the mouse model, some level of preexisting tolerance might exist 48 .
Box 1 | Prostate-specific antigen
Prostate-specific antigen (PSA) is a glycoprotein with expression mainly confined to the epithelial cells that line prostate glands. Disruption of the normal prostatic architecture owing to inflammation, infection or cancer leads to leakage of PSA into the general circulation, where it can be detected by an enzyme-linked immunosorbent assay (ELISA)-based blood test. In 1986, the US Food and Drug Administration (FDA) approved the use of PSA testing to monitor treatments for prostate cancer and, in 1994, testing of PSA levels was approved by the FDA for disease detection. PSA testing has low sensitivity and specificity for prostate cancer detection, and the value of PSA testing for preventing prostate cancer mortality has been evaluated in two recently published randomized trials, one of which supports testing 131 , whereas the second trial does not 132 . Nevertheless, the mortality rate from prostate cancer has declined slowly over the past decade, and there are some data to indicate that the initiation of this decline coincides with the adoption of PSA testing. The American Urological Association (AUA) recommends PSA screening for well-informed men with an estimated ten-year life expectancy 133 . This qualified screening recommendation is based on the notion that many screened men will be diagnosed with low-risk disease and thus face the therapeutic dilemma of whether to undergo primary therapy. In addition, the five-year survival rate for patients with prostate cancer is nearly 100%, so only men with a predicted lifespan long enough to benefit from intervention should probably undergo a screening PSA test. It is noteworthy that this screening recommendation is not shared by other organizations, most of which recommend against routine screening of asymptomatic men. From an immunological perspective, PSA is a target antigen in several immunotherapeutic approaches for prostate cancer, most notably a poxvirus-based vaccine known as ProstVac VF 54 .
Central deletion
Self tolerance that is created at the level of the central lymphoid organs. Developing T cells in the thymus, and B cells in the bone marrow, that strongly recognize self antigen face deletion or marked suppression.
Passive immunotherapy
The induction of immunity by the transfer of immuno globulins or T cells.
Active immunization
The induction of immunity by activation or expansion of the endogenous immune repertoire.
Poxvirus-based vectors. Viral vectors have several inher ent advantages for immunotherapy -they are straight forward to engineer, they can carry large amounts of genetic material and there is a great deal of clinical expe rience with poxvirus vectors, such as vaccinia virus, as they were used worldwide in the eradication of small pox 49 . In vivo, poxvirus vectors most probably infect epi thelial cells, a proportion of which undergo cell death. Cellular debris, including encoded antigens, is then taken up by nearby immature APCs, which, when appropriately activated, can present these antigens to CD4 + and CD8 + T cells in a proinflammatory context (FIG. 2a) . Direct infection of APCs, particularly the langerhans cells in the skin, is another mechanism by which poxvirus vec tors can prime an immune response. For prostate cancer, PSAtargeted vaccinia virusbased immunotherapy has proceeded through several steps, including the incor poration of DnA encoding costimulatory molecules (lymphocyte functionassociated antigen 3 (lFA3), CD80 and intercellular adhesion molecule 1 (ICAM1); known as TRICoM) into the vaccine 50 , as well as opti mization of the MHC class IIbinding properties of the vaccine antigen 51 . The main disadvantage of poxvirus based vectors results from the immunological proper ties that render poxviruses efficacious vaccine vectors: their propensity to induce a strong antibody response makes homologous prime-boost regimens ineffective, as the antibody response to viral proteins dominates over the desired response to encoded antigen (or anti gens) 52 . To circumvent this immunological limitation, a semiheterologous prime-boost strategy involving a vaccinia virus prime followed by an analogous fowlpox virus boost (ProstVac VF-TRICoM; Bavarian nordic) was optimized 53 . The clinical development of this agent has been recently reviewed 54 , and includes several tri als in which ProstVac VF was combined with other conventional or experimental agents 55 . Perhaps most relevant to the present discussion, several recent trials of ProstVac VF provide important immunological and clinical insights into cancer immunotherapy, which are described later.
Sipuleucel-T.
In contrast to the 'off the shelf ' nature of other immunotherapy agents, sipuleucelT (Provenge; Dendreon Inc.) is a personalized product that is indi vidually manufactured for each patient with prostate cancer 56 . It is similar in some ways to dendritic cell (DC) vaccines, which have been extensively studied in many tumour types 57 . First, leukopheresis is carried out, and monocytes are enriched in the leukopher esis product through density-gradient centrifuga tion. These cells are then incubated with the targeted immunogen, a fusion protein linking granulocytemacrophage colonystimulating factor (gMCSF) to PAP, before intravenous administration (FIG. 2b) . once infused, these autologous monocytes are thought to mature into functional APCs and to activate PAP specific CD4 + and CD8 + T cells in treated patients. These activated T cells are then thought to home to tumour lesions, mediating an antitumour response. In this approach, PAP was chosen as the target antigen based on preclinical studies in a rat model that showed that tolerance to PAP in prostate cancer was not medi ated by central deletion of PAPspecific T cells, such that PAPdirected vaccination could induce marked T cell infiltration into the prostate gland 58 . In terms of clinical development of immunotherapies for prostate cancer, this agent has progressed the furthest: three Phase III studies have been completed and US Food and Drug Administration (FDA) approval was granted in April 2010, making sipuleucelT the first antigenspecific immunotherapy approved for cancer treatment. These Phase III trials provide certain immunological insights, which are discussed further below. It should also be noted that this approach is adaptable to other tumour types by changing the nature of the immunogen -that is, by changing the antigen coupled to gMCSF in the fusion protein.
Additional approaches. An additional antigenspecific approach to cancer immunotherapy involves DnA based vaccines; in contrast to the above approaches which use viruses and patient monocytes as vectors, DnA can be rapidly and precisely synthesized, mak ing it straightforward to target nearly any selected anti gen 59 . The main disadvantage of DnAbased vectors is their low level of immunogenicity relative to the highly immunogenic viral vectors described above. To improve the outcome, proinflammatory molecules -such as herpes simplex virus type 1 tegument protein VP22 (to enhance spreading from transfected cells to DCs) or Tolllike receptor (TlR) agonists (to activate APCs) -have been incorporated into DnAbased vaccines 60 , or the vectors have been coadministered with gMCSF as a nonspecific adjuvant. In this context, gMCSF is thought to function through the recruitment of APCs, particularly DCs, to the vaccine site 61 . A recent clinical study 62 highlights the potential utility of DnAbased vectors in men with prostate cancer: in a population of men with biochemically recurrent disease given a DnA vaccine encoding PAP, PAPspecific T cell responses were induced, as well as an inhibition of the rate of PSA level increase.
Monoclonal antibodies specific for proteins expressed on the surface of tumour cells are a form of passive immunotherapy, which is in contrast to the above approaches, which are all examples of active immunization. Passive immunotherapy is now commonplace in mainstream clinical oncology, with antibodies spe cific for CD20 (such as rituximab (Rituxan/Mabthera; genentech/Roche/Biogen Idec)), human epidermal growth factor receptor 2 (trastuzumab (Herceptin; genentech/Roche)) and other tumour antigens being widely used. Analogous agents are in earlier stages of development in prostate cancer and focus mainly on PSMA as a target 63 . Interestingly, PSMA is overexpressed on tumourassociated vasculature, as well as on the cell surface of prostate cancer cells, making this agent poten tially applicable to other types of cancer 46 . early clinical trials of a humanized, PSMAspecific antibody (J591; Cornell Weill Medical College) showed impressive tumour targeting, but few objective clinical responses and is based on cells from a patient-derived leukopheresis product. These cells are sent to a central processing facility where monocytes are enriched by density-gradient centrifugation. These monocytes are incubated for 36-44 hours with a specific fusion protein, coupling granulocyte-macrophage colony-stimulating factor (GM-CSF) to the target antigen, in this case prostatic acid phophatase (PAP). In this approach, GM-CSF targets the fusion protein to immature DCs and enhances subsequent DC maturation. Following incubation, the product is sent to the clinic where it is administered intravenously. Once in the patient, the patient's immature monocytes are thought to mature to fully competent APCs, presenting PAP peptides to the host immune system in a manner that activates CD4 + and CD8 + T cells. c | J591 is an antigen-specific approach using a humanized monoclonal antibody specific for prostate-specific membrane antigen (PSMA). Although early trials used unlabelled antibody, current trials involve 177 Lu-labelled J591, a β-ray emitter with a half-life and path-length favourable for radiotherapy and immunotherapy. Here, the antibody specifically targets the radioactive isotope to the target tissue, where tumour cell death is mediated by irradiation. CDR, complementarity-determining region; TCR, T cell receptor.
were noted in the patients with advanced tumours who were included in these studies 64 . Similar to monoclonal antibodies developed for the treatment of other types of cancer, the current development of J591 has progressed to a radioisotopelabelled version, with the goal of mediating cancer cell death by localizing a radioactive βray emitter close to a patient's tumour mass 65 (FIG. 2c) . 66 . However, skewing of the immune response, as mediated by a potent monovalent antigenspecific immunotherapy, could theoretically lead to tumour anti gen loss, which has been documented in melanoma 67, 68 , although not in prostate cancer. Polyvalent immuno therapy vectors might avoid such a situation by simul taneously inducing an immune response to several tumourassociated antigens.
Several trials involving
Cell-based immunotherapy. The cellbased immuno therapy known as gVAX (BioSante) 69 is one example of a polyvalent approach to tumour immunotherapy, in which gMCSFtransduced tumour cells are used as a vaccine. Such cells are injected intradermally; the gMCSF attracts APCs and T cells to the vaccine site, thereby priming an immune response to tumour antigens 61, 70 (FIG. 3a) . earlier gVAX trials attempted to engineer a vaccine using autologous tumour cells from individual patients 71 , but it was later appreciated that tumour antigens can be crosspresented on patients' APCs 72 , so further clinical development focused on allogeneic tumour cell lines of a particular cancer type transduced to secrete gMCSF. This approach has been developed for several types of cancer, including pancre atic 73 , breast 74 , lung 75 , haematological 76 and prostate 70 cancers. Prostate gVAX, for example, includes the androgensensitive prostate cancer cell line lnCaP, as well as the castrationresistant prostate cancer cell line PC3 (FIG. 3a) , and early phase clinical trials suggested that prostate gVAX could induce new antibodies specific for the cell lines injected 77, 78 . Similar to sipuleucelT, clini cal development of prostate gVAX has advanced to the level of randomized Phase III clinical trials. However, for various reasons, these trials have so far not been successful 79 , providing important lessons regarding both clinical trial design and tumour immunology in humans (see below).
Immune checkpoint blockade. In addition to the vari ous immunotherapy approaches described above, recent studies in tumour immunology have focused on the concept of immune checkpoints -a series of molecules that function to limit an ongoing immune response [80] [81] [82] (FIG. 3b) . Furthest along in clinical development among the checkpoint inhibitors are antibodies specific for cytotoxic T lymphocyte anti gen 4 (CTlA4) (ipilimumab (MDX010; BristolMyers Squibb/Medarex) and tremelimumab (CP675206; Pfizer)). The importance of CTlA4 in restraining the immune response was apparent from early mouse stud ies, in which Ctla4knockout mice died at ~4-6 weeks of age from a lymphoproliferative disorder 83, 84 . CTlA4 blockade has been evaluated in several malignancies, but the most welldeveloped data come from trials in patients with melanoma, in which the blocking agent is associated with an approximate 10% objective response rate but, also, (as might have been predicted from the knockout mice) a significant rate (25-35%) of clini cally important immunerelated toxicity 85 . These data are noteworthy as few significant objective responses have been noted in cancer vaccine trials 86 ; these clini cal data indicate that blocking immune checkpoints that restrain existing antitumour immune responses might be more effective than inducing a de novo anti tumour response through vaccination. These data also support the notion that certain patients with cancer might have a population of tumourspecific T cells that are poised to mediate an antitumour response but that are effectively restrained by CTlA4 expres sion. Ipilimumab has been evaluated in several Phase I and Phase II trials in patients with prostate cancer, and objective clinical responses and decreases in PSA levels have been described 87 . Based on those data, a Phase III trial comparing ipilimumab with a pla cebo is currently underway in men with castration resistant metastatic disease who have not responded to prior chemotherapy (www.ClinicalTrials.gov, identifier: nCT00861614).
Another immunological checkpoint that has been targeted recently in clinical trials is that mediated by the molecule known as programmed cell death 1 (PD1). PD1 was initially identified in a librarybased screen of CD8 + T cells undergoing apoptosis 88 . Subsequent work identified the ligand for PD1 as B7H1 (also known as PDl1) 89, 90 and showed that the interaction between PD1 and B7H1 leads to an inhibition of T cell function. In animal studies, PD1 blockade potenti ates an antitumour immune response [91] [92] [93] , and PD1 deficient animals develop a degree of strainspecific autoimmunity (albeit with a milder phenotype than Ctla4knockout mice) 94, 95 . Perhaps most importantly, human studies showed that increased expression of B7H1 was associated with a poor clinical outcome in several tumour types, most notably in renal cell car cinoma 96 . PD1 has been less well studied in prostate cancer, although we have found that the CD8 + T cells that infiltrate the prostate gland in men with cancer seem to express PD1 (ReF. 97) . Similar findings were recently reported in patients with melanoma, suggest ing that PD1 expression by tumourinfiltrating lym phocytes might be a common occurence 98 . A Phase I clinical trial of a fully human monoclonal antibody targeting PD1 (MDX1106; BristolMeyers Squibb) has been completed, with interesting results 99 . First, this agent was remarkably well tolerated, with few serious adverse events noted. Second, several objective clinical responses were noted in patients with various types of cancer, which is unusual for a Phase I trial of immunotherapy in a heavily pretreated patient popu lation. Taken together, these data reinforce the relative importance of immune checkpoint blockade in tumour immunotherapy. In addition, if confirmed in larger studies, it would seem that the benign toxicity profile of PD1 blockade could render it an ideal candidate for future combinatorial trials. The injected vaccine tumour cells undergo necrosis, and cellular debris is taken up by the recruited DCs. Next, the DCs must mature to effectively prime an immune response; GM-CSF secreted by the vaccine cells probably has a role here as well. In the prostate GVAX approach, the injected cancer cells are allogeneic with respect to treated patients, so this immunotherapy relies on cross-presentation to prime a CD8 + T cell antitumour immune response. The prostate cancer cell lines used are LNCaP and PC3, which are androgen-sensitive and castration-resistant prostate cancer cells, respectively. b | The immune checkpoint blockade approach is exemplified by antibodies specific for cytotoxic T lymphocyte antigen 4 (CTLA4) (such as ipilimumab and tremelimumab), which block the immunosuppression mediated by the interaction between CD80 and CD86 (on APCs) and CTLA4 (on CD8 + and CD4 + T cells). A second important immune checkpoint, mediated by the interaction between programmed cell death 1 (PD1) on T cells and its ligand B7-H1 (also known as PDL1) on either APCs or tumour cells, has been the subject of several recent early phase clinical trials. The interaction between lymphocyte activation gene 3 (LAG3) on T cells and MHC class II molecules on APCs is also inhibitory; indeed, CD8 + T cell unresponsiveness may depend on the interaction of several, non-overlapping checkpoints. TCR, T cell receptor.
Primary endpoint
The main result that is measured at the end of a clinical trial to determine whether the hypothesis under study has been fulfilled.
RECIST
(Response evaluation criteria in solid tumours). A set of formally defined rules used to measure objective clinical responses in cancer patients treated with a particular therapy. These parameters measure a series of index lesions and quantify whether the lesions have decreased in size.
Single-armed trial
A clinical trial without a concurrent control group.
Halabi nomogram
A model that uses historical data to estimate the survival of patients with progressive prostate cancer after castration.
Clinical trials of prostate cancer immuno therapy Several of the immunotherapy approaches for prostate cancer discussed above have been tested in large clinical trials (TABLe 1) ; a targeted overview of these trials can give unique insights into immunotherapy that might apply to other solid tumours. In addition, these trials provide inter esting data regarding the translation of immunological concepts from the laboratory to a clinical setting.
Survival is the most robust clinical trial endpoint. Similar to the readout in a laboratory experiment, a clinical trial must also have a readout, known as a primary endpoint. Clinical trials in patients with cancer often use some measure of tumour progression as the primary endpoint, quantified by a set of formalized criteria known as ReCIST (response evaluation criteria in solid tumours) or World Health organization (WHo) criteria. It is important to note that the ReCIST system was developed in the era of cytotoxic chemotherapy, and so these criteria are based on two implicit assumptions: effective therapies shrink tumours, and tumour shrinkage translates to patient benefit 100 . So, a typical endpoint for an oncology clinical trial might be time to tumour progression (TTP), with progression assayed by ReCIST. Indeed the first random ized Phase III trial of sipuleucelT (the D9901 trial) 101 was designed with a TTP endpoint, as was a recently pub lished randomized Phase II trial of ProstVac VF 102 . A sta tistically significant difference in TTP was not observed between the active immunotherapy and placebo groups in either case. By contrast, both trials showed a clear and statistically significant difference in overall survival between immunotherapy and placebo groups. This observation is consistent with the results of a recently reported randomized Phase III trial of ipilimumab in patients with metastatic melanoma, for which improved survival rates were observed despite a low rate (11%) of objective clinical responses 103 . The mechanisms behind this discrepancy are not completely understood, but they might involve tumour progression before shrink age, delayed responses and/or prolonged disease stabi lization leading to clinical benefit. Modified versions of ReCIST and WHo criteria have been proposed, which use alternative definitions of a response and so might more accurately assess the potential clinical benefits of immunotherapy 104 . However, reliance on overall sur vival as a clinical trial endpoint means that trial regis tration for men with prostate cancer is currently limited to patients with castrationresistant metastatic disease, which, given the belief that cancer immunotherapy is probably most efficacious in a minimal residual disease setting 105 , means that such trials might not indicate the true potential of a therapy.
Immunotherapy might be more efficacious with a lower disease burden. Although an inverse relationship between tumour burden and immunotherapy response might seem intuitively obvious 106 , there is some con troversy surrounding this idea, as objective clinical responses have been noted in patients with advanced cancers treated with adoptive T cell therapy 107 , as well as in patients with several tumour types treated with checkpoint blockade 108 . nevertheless, a recently pub lished retrospective study of men with prostate cancer enrolled on a Phase II single-armed trial of ProstVac VF provides some clinical evidence for this concept. Here, a wellestablished predictive algorithm, the Halabi nomogram 109 , was used to stratify patients into those with predicted survival duration greater than or less than the median at the time of trial enrolment 105 . Interestingly, patients with less advanced disease (those with a Halabi predicted survival duration greater than the median) seemed to benefit clinically from immunotherapy with ProstVac VF, in that their observed survival was sig nificantly longer than predicted. Conversely, patients with a predicted survival duration less than the median seemed not to have any survival benefit from the immunotherapy under study.
Phase III trials should be based on data from Phase II studies. In contrast to Phase III trials in other medical disciplines, such trials often end in failure in patients with cancer -the agent under study does not produce the clinical benefit that the trial was intended to assay 110 . Several hypotheses have been put forward to explain this issue, but perhaps the simplest concerns Phase II trials, which are usually carried out to more accurately quantify the clinical benefit of an agent or approach before moving to a larger, more expensive Phase III study. Although the positive predictive value of Phase II trials for Phase III outcome is not particularly robust, the negative predictive value is strong: a negative Phase II trial in oncology clearly predicts a negative Phase III result 111 . This issue is exem plified by the development of gVAX immunotherapy for prostate cancer. early (Phase II) studies established the safety of gVAX 71 , and immunological correlates (the development of tumour antigenspecific antibodies) were used to select a dosing regimen 112 . However, in these Phase II studies, gVAX was never compared directly with chemotherapy, and it was not administered in sequence with chemotherapy. nevertheless, two Phase III trials were launched -both of which used a chemotherapy comparator group. In the first trial (VITAl1), gVAX immunotherapy was directly compared with chemo therapy in men with asymptomatic, castrationresistant prostate cancer, despite the fact that few radiographically detectable responses were noted in the Phase II gVAX studies. A second Phase III trial (VITAl2) was subse quently initiated to test the hypothesis that the combi nation of immunotherapy plus chemotherapy would extend survival in men with more advanced (sympto matic), metastatic disease. Although chemotherapy had been shown to be at least additive with immunotherapy in animal studies 113 , no Phase II trials were carried out to verify this result in humans or to explore dose and sched ule questions. A planned interim analysis of VITAl2 showed a greater number of deaths in patients treated with the combination of gVAX plus chemotherapy and the trial was closed. Unfortunately, this imbalanced out come has yet to be explained, by either immunological or clinical mechanisms. These events led to an unplanned interim analysis of the earlier trial (VITAl1), which showed that the trial was unlikely to meet its primary (survival) endpoint and should be stopped. In hindsight, these data emphasize the importance of Phase II test ing, in particular for combination approaches in which dosing and timing might be crucial 41, 114 .
Combination immunotherapy
Most treatment regimens for patients with advanced can cer include a combination of chemotherapy drugs, or a combination of radiation therapy and chemotherapy. So, it is possible that cancer immunotherapy will need to be combined with conventional therapy to achieve maximal patient benefit. Fortunately, many conventional treatments for prostate and other cancers have beneficial immunological effects (see below), making combinato rial trials an attractive proposition. even chemotherapy, which is broadly viewed as immunosuppressive, might to some extent boost an antitumour response 115 . However, issues of dose and schedule could be crucial, and Phase II trials are required to explore such issues before the initiation of larger studies.
Androgen ablation. The immunological effects of andro gen ablation are surprising because they involve the thymus, which is generally not thought of as an androgen sensitive organ 25 
. In aged mice, androgen ablation seems to result in regeneration of the normally involuted thymus and in the output of new T cells, as assayed by increased numbers of T cell receptor excision circles in the peripheral blood 29 . Similar effects have been observed in humans. As noted above, androgen ablation before prostate cancer surgery results in the infiltration of CD4 + T cells into the prostate gland, and these cells have an activated phenotype 26 . Also supporting a proimmuno genic role for androgen ablation are recent data show ing the induction of new antibody specificities in treated patients 116, 117 . So, the notion that androgen ablation might enhance an antiprostate cancer immune response has a strong scientific basis and has been evaluated in several clinical trials. An early study tested one dose of vac cinia virus-PSA vaccine (ProstVac) in combination with androgen ablation, finding the combination to be [136] [137] [138] [139] [140] .
Hypophisitis
Inflammation of the pituitary gland, which can be induced in patients with cancer by CTLA4-blocking antibodies. Clinically, hypophysitis is characterized by decreased levels of thyroid hormone, cortisol and other hormones.
well tolerated 118 . In a later randomized study, immune responses to ProstVac were more commonly observed in men who received androgen ablation after active immunotherapy 119 , as opposed to receiving androgen ablation before immunotherapy. SipuleucelT has also been tested in combination with androgen ablation; in this case, immunotherapy was administered after androgen ablation, but data from this study have yet to be published. Taken together, these studies support the notion that combined immune and hormonal therapy might be clinically interesting and worthy of further evaluation. Although this concept could conceivably be applied to other hormonesensitive cancers, such as breast cancer, we are not aware of any such clinical trials at this time.
Radiotherapy. Although the cytotoxic effects of radia tion therapy are well appreciated, recent data support the notion that irradiation of cancer cells can prime an antitumour immune response 120 . on a cellular basis, this process seems to involve the uptake of dying tumour cells by APCs 121 and the presentation of tumour antigens to immune cells, as well as the induction of a proinflam matory microenvironment by the radiation 122 . In patients with prostate cancer, evidence for an immunological effect of radiotherapy is provided by data showing the induction of new antibody specificities following radio therapy treatment 116 . Although the molecular mecha nisms for these immunological effects of radiotherapy are complex 115 , recent work has shown that high mobility group box 1 (HMgB1) released from dying tumour cells can function as a TlR4 agonist, activating APCs in either the tumour parenchyma or in the draining lymph node (or nodes), and so priming an immune response 120 . It should be noted that these immunostimulatory effects are not unique to radiationinduced tumour cell death and can also be elicited when tumour cells are killed by certain chemotherapy agents. Several preclinical stud ies support the notion that combining irradiation with immunotherapy can be either additive or synergistic in terms of the antitumour response 123, 124 . This concept has been evaluated clinically in a small randomized trial of men undergoing primary radiotherapy for prostate cancer 125 ; 13 out of 17 patients in the radiotherapy and immunotherapy combination treatment group had a greater than threefold increase in the number of PSA specific T cells, whereas no increase in the number of PSAspecific T cells was noted in the group that received radiotherapy alone. However, as is the case for combin ing chemotherapy with immunotherapy, the relative sequencing of agents might be crucial 126 . An ongoing, randomized Phase III trial of ipilimumab in men with metastatic castrationresistant prostate cancer, who have failed chemotherapy, includes a low dose of radio therapy in an effort to prime an initial antitumour immune response. As radiotherapy is routinely used in the pri mary therapy of several tumour types, combination radiotherapy and immunotherapy might be of increasing interest as specific immunotherapy agents are developed for other types of cancer.
Checkpoint blockade.
A new approach to immunotherapy involves the combination of several immunological agents to both prime an antitumour response and prevent the suppression of existing and new responses. In pros tate cancer, the first published data come from a study combining a CTlA4specific antibody (ipilimumab) with gMCSF in an effort to stimulate an endogenous antitumour immune response 48 . At higher doses of ipilimumab, radiographically detectable antitumour responses were noted; the data strongly suggested a threshold dosing effect, with responses noted at levels of ipilimumab greater than 3 mg per kg. Another rel evant concept might be to combine an active, specific immuno therapy with an immune checkpointblocking agent. In an early clinical test of this concept, pros tate gVAX was combined with ipilimumab in a dose escalation study 127 . Decreases in PSA levels, as well as radiographically detectable tumour responses, were noted but, as is sometimes the case with ipilimumab, these responses were associated with immunerelated adverse events, including hypophisitis
128
. A similar com bination study has been carried out with ProstVac VF, the results of which are currently pending, and a trial combining pancreatic gVAX with ipilimumab is in early stages of accrual. It should be noted that the incidence of highgrade toxicity of ipilimumab may be a limiting fac tor in these studies. Should PD1specific antibodies prove to be better tolerated, but still effective as a checkpoint inhibitor, combination trials with PD1specific antibodies might be more feasible to design and complete.
In summary, there is a strong scientific rationale for combining different types of immunotherapy, as well as for combining immunotherapy with conventional therapy. In some types of cancer, such as breast cancer, these approaches might include tumourtargeted mono clonal antibodies 129 or targeted drugs such as imatinib for chronic myelogenous leukaemia 130 . But such approaches add complexity to clinical trial design, and issues of dosing and sequence are a notable challenge.
Box 2 | Immunological effects of androgen ablation
Androgen ablation -which is usually carried out chemically by administration of a leuteinizing-hormone-releasing hormone (LHRH) agonist such as leuprolide acetate or zoledronic acid -is by far the most common treatment for prostate cancer, in patients with both biochemically recurrent and metastatic disease. Recent studies have documented profound immunological effects of this common pharmacological therapy, all of which would be expected to enhance an antitumour immune response:
• CD4 + T cell infiltration into the prostate gland 26 ;
• Increase in CD8 + T cell and macrophage density in the prostate gland 27 ;
• Mitigation of CD4 + T cell tolerance to a prostate-and prostate cancer-restricted antigen 28 ;
• Reversal of thymic involution in aged mice 29 
;
• Increase in thymic output of T cells 29 ;
• Enhancement of efficacy of immunotherapy in animal models 31 .
Several groups have attempted to make use of these effects in a clinical trial setting 25 ; one notable ongoing trial combines androgen ablation with blockade of the immune checkpoint molecule cytotoxic T lymphocyte antigen 4 (CTLA4) using the monoclonal antibody ipilimumab (MDX-010; Bristol-Myers Squibb/Medarex) in men undergoing surgical resection for prostate cancer (www.ClinicalTrials.gov identifier: NCT00170157).
